NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT00000684

Locations: 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma

Phase 1

Completed

Conditions: Sarcoma, Kaposi
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 42

Registration Number: NCT00000763

Locations: 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States

and more 3 locations

A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 32

Registration Number: NCT00000645

Locations: 🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸
University of Minnesota, ACTU, Minneapolis, Minnesota, United States
🇺🇸
NY Univ. HIV/AIDS CRS, New York, New York, United States

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT00000696

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸
Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans, Louisiana, United States

and more 3 locations

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

Phase 3

Completed

Conditions: Mycobacterium Avium-intracellulare Infection
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1100

Registration Number: NCT00001030

Locations: 🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States

and more 39 locations

Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection

Phase 1

Withdrawn

Conditions: Communicable Diseases
Healthy

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00006630

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT00006291

Locations: 🇺🇸
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States
🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸
USC CRS, Los Angeles, California, United States

and more 23 locations

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 472

Registration Number: NCT00005758

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Stanford CRS, Palo Alto, California, United States
🇺🇸
Ucsf Aids Crs, San Francisco, California, United States

and more 14 locations

Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV

Phase 2

Withdrawn

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00021762

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

Phase 2

Completed

Conditions: HIV Infections
Leukoencephalopathy, Progressive Multifocal

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 90

Registration Number: NCT00001048

Locations: 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy